{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:42:34Z","timestamp":1784590954756,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Chagas disease is caused by the protozoan parasite <jats:italic>Trypanosoma cruzi<\/jats:italic>, and it is the most important neglected tropical disease in the Americas. Two drugs are available to treat the infection, but their efficacy in the chronic stage of the disease, when most cases are diagnosed, is reduced. Their tolerability is also hindered by common adverse effects, making the development of safer and efficacious alternatives a pressing need. <jats:italic>T. cruzi<\/jats:italic> is unable to synthesize purines de novo, relying on a purine salvage pathway to acquire these from its host, making it an attractive target for the development of new drugs. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated the anti-parasitic activity of 23 purine analogs with different substitutions in the complementary chains of their purine rings. We sequentially screened the compounds' capacity to inhibit parasite growth, their toxicity in Vero and HepG2 cells, and their specific capacity to inhibit the development of amastigotes. We then used in-silico docking to identify their likely targets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight compounds showed specific anti-parasitic activity, with IC<jats:sub>50<\/jats:sub> values ranging from 2.42 to 8.16 \u03bcM. Adenine phosphoribosyl transferase, and hypoxanthine-guanine phosphoribosyl transferase, are their most likely targets. <\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our results illustrate the potential role of the purine salvage pathway as a target route for the development of alternative treatments against <jats:italic>T. cruzi<\/jats:italic> infection, highlithing the apparent importance of specific substitutions, like the presence of benzene groups in the C8 position of the purine ring, consistently associated with a high and specific anti-parasitic activity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2022.1067461","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T05:35:55Z","timestamp":1673588155000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Identification of compounds with activity against Trypanosoma cruzi within a collection of synthetic nucleoside analogs"],"prefix":"10.3389","volume":"12","author":[{"given":"Berta","family":"Barnadas-Carceller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Martinez-Peinado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C\u00f3rdoba","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Ros-Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Gabald\u00f3n-Figueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Diaz-Mochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Gascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio J.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Pineda de las Infantas y Villatoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Alonso-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1093\/jac\/dkx516","article-title":"What to expect and when: Benznidazole toxicity in chronic Chagas\u2019 disease treatment","volume":"73","author":"Aldasoro","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116577","article-title":"Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for chagas disease","volume":"58","author":"Beltran-Hortelano","year":"2022","journal-title":"Bioorg Med. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0166-6851(81)90049-9","article-title":"Purine metabolism in Trypanosoma cruzi","volume":"3","author":"Berens","year":"1981","journal-title":"Mol. Biochem. Parasitol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.2174\/092986710791556023","article-title":"Inhibitors of the purine salvage pathway: A valuable approach for antiprotozoal chemotherapy","volume":"17","author":"Berg","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000384","article-title":"Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening","volume":"3","author":"Bettiol","year":"2009","journal-title":"PloS Negl. Trop. Dis."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113101","article-title":"Synthesis and evaluation of a collection of purine-like c-nucleosides as antikinetoplastid agents","volume":"212","author":"Bouton","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1128\/AAC.40.11.2592","article-title":"Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase","volume":"40","author":"Buckner","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"B500","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab168","article-title":"7-Aryl-7-deazapurine 3'-deoxyribonucleoside derivative as a novel lead for Chagas' disease therapy: In vitro and in vivo pharmacology","volume":"3","author":"Cardoso-Santos","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"B9","unstructured":"CDC - Chagas disease - biology2021"},{"key":"B10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s12272-014-0502-6","article-title":"HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics","volume":"38","author":"Cho","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41579-022-00777-y","article-title":"Anti-trypanosomatid drug discovery: Progress and challenges","author":"De Rycker","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1128\/AAC.41.8.1686","article-title":"Hypoxanthine phosphoribosyltransferase from Trypanosoma cruzi as a target for structure-based inhibitor design: Crystallization and inhibition studies with purine analogs","volume":"41","author":"Eakin","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf Model."},{"key":"B14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein\u2013ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"Forli","year":"2016","journal-title":"Nat. Protoc."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112020","article-title":"Advances in the treatment of Chagas disease: Promising new drugs, plants and targets","volume":"142","author":"Garc\u00eda-Huertas","year":"2021","journal-title":"BioMed. Pharmacother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/jcb.25978","article-title":"Transcriptome and functional genomics reveal the participation of adenine phosphoribosyltransferase in Trypanosoma cruzi resistance to benznidazole","volume":"118","author":"Garc\u00eda-Huertas","year":"2017","journal-title":"J. Cell Biochem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0020-711x(79)90065-x","article-title":"A re-examination of purine and pyrimidine synthesis in the three main forms of Trypanosoma cruzi","volume":"10","author":"Gutteridge","year":"1979","journal-title":"Int. J. Biochem."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2946-4-17","article-title":"Avogadro: An advanced semantic chemical editor, visualization, and analysis platform","volume":"4","author":"Hanwell","year":"2012","journal-title":"J. Cheminform."},{"key":"B19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s0006-2952(01)00644-x","article-title":"Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum","volume":"62","author":"Harmse","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9287","DOI":"10.1093\/jacamr\/dlab168","article-title":"Discovery of novel 7-aryl 7-deazapurine 3\u2032-deoxy-ribofuranosyl nucleosides with potent activity against Trypanosoma cruzi","volume":"61","author":"Hulpia","year":"2018","journal-title":"J. Med. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1086\/656917","article-title":"Tolerance and safety of nifurtimox in patients with chronic chagas disease","volume":"51","author":"Jackson","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/nar\/gkz424","article-title":"PrankWeb: A web server for ligand binding site prediction and visualization","volume":"47","author":"Jendele","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/nar\/gkaa971","article-title":"- PubChem in 2021: New data content and improved web interfaces","volume":"47","author":"Kim","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.actatropica.2019.105107","article-title":"Drug discovery for chagas disease: A viewpoint","volume":"198","author":"Kratz","year":"2019","journal-title":"Acta Trop."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2019.00166","article-title":"Chagas disease: From discovery to a worldwide health problem","volume":"7","author":"Lidani","year":"2019","journal-title":"Front. Public Health"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202100095","article-title":"Synthesis and screening of 6-alkoxy purine analogs as cell-type selective apoptotic inducers in jurkat cells","volume":"354","author":"Lorente","year":"2021","journal-title":"Archiv der Pharmazie."},{"key":"B29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s13071-020-04171-6","article-title":"Amaryllidaceae alkaloids with anti-Trypanosoma cruzi activity","volume":"13","author":"Martinez-Peinado","year":"2020","journal-title":"Parasit Vectors."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9020406","article-title":"Identification of Trypanosoma cruzi growth inhibitors with activity in vivo within a collection of licensed drugs","volume":"9","author":"Martinez-Peinado","year":"2021","journal-title":"Microorganisms"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070638","article-title":"Novel purine chemotypes with activity against Plasmodium falciparum and Trypanosoma cruzi","volume":"14","author":"Martinez-Peinado","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020688","article-title":"Anti-Trypanosoma cruzi activity of metabolism modifier compounds","volume":"22","author":"Martinez-Peinado","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41564-022-01211-y","article-title":"Discovery of an orally active benzoxaborole prodrug effective in the treatment of chagas disease in non-human primates","volume":"7","author":"Padilla","year":"2022","journal-title":"Nat. Microbiol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/srep08771","article-title":"New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: An open resource","volume":"5","author":"Pe\u00f1a","year":"2015","journal-title":"Sci. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","article-title":"Chagas disease","volume":"391","author":"P\u00e9rez-Molina","year":"2018","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/srep09139","article-title":"Amide-controlled, one-pot synthesis of tri-substituted purines generates structural diversity and analogues with trypanocidal activity","volume":"5","author":"Pineda de las Infantas","year":"2015","journal-title":"Sci. Rep."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105906","article-title":"Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: A review","volume":"55","author":"Santos","year":"2020","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B38","unstructured":"Schr\u00f6dingerL.\n            DeLanoW.\n          2020"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/mp\/sss065","article-title":"Improved growth and stress tolerance in the arabidopsis oxt1 mutant triggered by altered adenine metabolism","volume":"5","author":"Sukrong","year":"2021","journal-title":"Mol. Plant"},{"key":"B32","doi-asserted-by":"publisher","first-page":"ciac579","DOI":"10.1093\/cid\/ciac579","article-title":"A phase-2, randomized, multicenter, placebo-controlled, proof-of-concept trial of oral fexinidazole in adults with chronic indeterminate Chagas disease","author":"Torrico","year":"2022","journal-title":"Clin Infect Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.bmc.2017.02.016","article-title":"Synthesis and activity of nucleoside-based antiprotozoan compounds","volume":"25","author":"Tran","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/17460441.2020.1681394","article-title":"Why hasn't there been more progress in new Chagas disease drug discovery","volume":"15","author":"Vermelho","year":"2020","journal-title":"Expert Opin. Drug Discovery"},{"key":"B42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/protein\/8.2.127","article-title":"LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions","volume":"8","author":"Wallace","year":"1996","journal-title":"Protein Eng."},{"key":"B43","unstructured":"WHO fact sheets, Chagas disease2021"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1067461\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T05:35:58Z","timestamp":1673588158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1067461\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":43,"alternative-id":["10.3389\/fcimb.2022.1067461"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.1067461","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"article-number":"1067461"}}